Methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate

We are Methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate CAS:10399-13-0 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: Methyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
CAS.NO:  10399-13-0
Synonyms:
Methyl 2-Cyclohexyl-2-hydroxyphenylacetate
Cyclohexyl 2-hydroxy-2-phenylpropanoate
Benzeneacetic acid, α-hydroxy-α-methyl-, cyclohexyl ester
Methyl cyclohexylphenylglycolate

Molecular Formula:  C15H20O3
Molecular Weight: 248.31700

Physical and Chemical Properties:
Density: 1.1±0.1 g/cm3
Boiling point: 375.4±22.0 °C at 760 mmHg
Melting point: 118-120 °C(lit.)
Flash point: 154.0±15.1 °C
Refractive index:1.544

Specification:
Appearance: white crystalline powder
Purity:≥98%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:-20ºC Freezer.Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Oxybutynin hydrochloride  CAS:1508-65-2
Intermediates of Oxybutynin  CAS:5633-20-5

Related News: The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry.848133-76-6 Bulk bulk medicines: overcapacity, low prices, future capacity and output will be reduced, and it is possible to transfer foreign production.5-(3-Fluorophenyl)-2-methylpyridine CAS:713143-67-0 Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis.6-ethynyl-4,4-dimethyl-2,3-dihydrothiochromene The CRL for the Cabenuva injection, containing two active ingredients cabotegravir and Janssen’s rilpivirine, follows U.S. market approval in April for its once-a-day pill Dovato, also a two-drug combination.This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them.